SAB Biotherapeutics (SABS) to Release Earnings on Wednesday

SAB Biotherapeutics (NASDAQ:SABS) is anticipated to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 7:00 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27). On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $3.25 on Tuesday. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60. The company’s 50 day moving average price is $2.40 and its two-hundred day moving average price is $2.13. The stock has a market cap of $33.83 million, a P/E ratio of -0.81 and a beta of 0.60. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 0.27.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wall Street Zen upgraded SAB Biotherapeutics to a “sell” rating in a research note on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of SAB Biotherapeutics in a research note on Tuesday, October 14th. Leerink Partners assumed coverage on SAB Biotherapeutics in a research note on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price objective on the stock. HC Wainwright decreased their target price on SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of SAB Biotherapeutics in a research report on Friday, September 19th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.